

**2018 Mo-99 TOPICAL MEETING ON
MOLYBDENUM-99 PRODUCTION TECHNOLOGY DEVELOPMENT**

**SEPTEMBER 23-26, 2018
HILTON KNOXVILLE HOTEL
KNOXVILLE, TN**

Updates on Implementation of Cyclotron-Produced Tc-99m

J. Kumlin¹, F. Bénard², K.R. Buckley², M. Dodd², V. Hanemaayer², B. Hook¹, M. Kovacs²
S. McDiarmid², F.S. Prato², T. Ruth², J.F. Valliant², M. Vuckovic², S. Zeisler²,
M. Cross¹, S. Foster^{1,2}, F. Gleeson^{1,2}, J. Hanlon², K. Hayashi¹, J. McCann², J. Schlosser^{1,2},
K. Wilson¹, P. Schaffer^{1,2}

- 1) ARTMS Products Inc.
3800 Wesbrook Mall, Vancouver BC, V6S 2L9 – Canada
- 2) The ITAP Consortium
4004 Wesbrook Mall, Vancouver BC, V6T 2A3 – Canada

ABSTRACT

ARTMS Products, Inc. holds the global commercialization rights to technology created by a consortium of research organizations including TRIUMF, BC Cancer – Vancouver, Lawson Health Research Institute (LHRI) and the Centre for Probe Development and Commercialization (CPDC), for producing the world's most-used diagnostic imaging isotope, technetium-99m (Tc-99m), using local, hospital-based medical cyclotrons.

This presentation will provide a status update on the implementation of commercial scale (TBq) direct cyclotron-production of Tc-99m by proton irradiation of Mo-100 targets. ARTMS radioisotope processing hardware meets safety and electrical standards in Europe and North America. Strategic demonstration facilities in Canada and the UK are identified and are being equipped for routine production of Tc-99m on medical cyclotrons.